Immix Biopharma, Inc. Common Stock earnings per share and revenue
On 07 de nov. de 2025, IMMX reported earnings of -0.24 USD per share (EPS) for Q3 25, missing the estimate of -0.19 USD, resulting in a -23.84% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a +2.86% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analistas forecast an EPS of -0.16 USD, with revenue projected to reach -- USD, implying an diminuir of -33.33% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were Immix Biopharma, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Immix Biopharma, Inc. Common Stock reported EPS of -$0.24, missing estimates by -23.84%, and revenue of --, -- -- expectations.
How did the market react to Immix Biopharma, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 2.86%, changed from $3.15 before the earnings release to $3.24 the day after.
When is Immix Biopharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for 23 de mar. de 2026.
What are the forecasts for Immix Biopharma, Inc. Common Stock's next earnings report?
Based on 3
analistas, Immix Biopharma, Inc. Common Stock is expected to report EPS of -$0.16 and revenue of -- for Q4 2025.